(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.34% ¥ 2 300.00
Live Chart Being Loaded With Signals
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors...
Stats | |
---|---|
Объем за сегодня | 3.19M |
Средний объем | 2.18M |
Рыночная капитализация | 1 048.85B |
EPS | ¥0 ( 2024-01-30 ) |
Дата следующего отчета о доходах | ( ¥51.38 ) 2024-05-08 |
Last Dividend | ¥37.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 8.71 |
ATR14 | ¥1.094 (0.05%) |
Объем Корреляция
Ono Pharmaceutical Co., Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Ono Pharmaceutical Co., Корреляция - Валюта/Сырье
Ono Pharmaceutical Co., Финансовые показатели
Annual | 2022 |
Выручка: | ¥447.19B |
Валовая прибыль: | ¥337.13B (75.39 %) |
EPS: | ¥230.85 |
FY | 2022 |
Выручка: | ¥447.19B |
Валовая прибыль: | ¥337.13B (75.39 %) |
EPS: | ¥230.85 |
FY | 2022 |
Выручка: | ¥361.36B |
Валовая прибыль: | ¥267.85B (74.12 %) |
EPS: | ¥162.19 |
FY | 2021 |
Выручка: | ¥309.28B |
Валовая прибыль: | ¥223.71B (72.33 %) |
EPS: | ¥151.11 |
Financial Reports:
No articles found.
Ono Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥33.00 (N/A) |
¥0 (N/A) |
¥37.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥6.80 | 2001-03-27 |
Last Dividend | ¥37.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 41 | -- |
Total Paid Out | ¥671.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.16 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.64 | |
Div. Directional Score | 9.16 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8136.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
7483.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6707.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
6058.T | Ex Dividend Junior | 2024-02-28 | Sporadic | 0 | 0.00% | |
4733.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3981.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3186.T | Ex Dividend Junior | 2023-11-29 | Annually | 0 | 0.00% | |
2180.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
9052.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
7942.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.256 | 1.500 | 4.88 | 7.31 | [0 - 0.5] |
returnOnAssetsTTM | 0.143 | 1.200 | 5.23 | 6.28 | [0 - 0.3] |
returnOnEquityTTM | 0.166 | 1.500 | 9.26 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.291 | -1.000 | 7.09 | -7.09 | [0 - 1] |
currentRatioTTM | 3.95 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.140 | 1.500 | 4.78 | 7.17 | [0.2 - 2] |
debtRatioTTM | 0.00963 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 99.03 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 222.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 191.88 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0109 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.756 | 1.000 | 0.740 | 0.740 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.329 | 1.000 | 5.41 | 5.41 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 12.35 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.559 | 0.800 | 9.61 | 7.69 | [0.5 - 2] |
Total Score | 12.67 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.58 | 1.000 | 9.23 | 0 | [1 - 100] |
returnOnEquityTTM | 0.166 | 2.50 | 9.53 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 191.88 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.48 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 222.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.291 | 1.500 | 7.09 | -7.09 | [0 - 1] |
pegRatioTTM | -1.449 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.213 | 1.000 | 7.18 | 0 | [0.1 - 0.5] |
Total Score | 5.64 |
Ono Pharmaceutical Co.,
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа